Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sarconeos - Biophytis

Next Previous
Drug Profile

Sarconeos - Biophytis

Alternative Names: 20-hydroxyecdysone - Biophytis; BIO 101; RUVEMBRI

Latest Information Update: 22 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biophytis
  • Class Cyclopentanes; Ketones; Obesity therapies; Phenanthrenes; Small molecules
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections; Sarcopenia; Sarcopenia

Highest Development Phases

  • Phase III SARS-CoV-2 acute respiratory disease
  • Phase II Sarcopenia
  • Phase I Obesity
  • No development reported Duchenne muscular dystrophy

Most Recent Events

  • 09 Sep 2026 Biophytis plans to submit a protocol amendment for the phase II OBA clinical study in Obesity to the US FDA and the European Medicines Agency (EMA)in the coming days
  • 09 Sep 2026 Biophytis submits a protocol amendment to the Brazilian Health Regulatory Agency (ANVISA) for the phase II OBA clinical study in Obesity
  • 31 Aug 2026 Biophytis plans the phase II OBA trial for Obesity (Treatment-experienced, Combination therapy) in USA, Brazil, and Europe (PO) in the first quarter of 2027 (NCT07411378)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top